ALK and non-small cell lung carcinoma: Although many improvements have been made in NSCLC therapy, including the introduction of targeting epidermal growth factor receptor (EGFR) mutations or ALK rearrangements, immunotherapy and surgery, the prognosis of NSCLC patients is still dismal.